Cardiac arrest & resuscitation
Association between metformin and survival outcomes in in-hospital cardiac arrest patients with diabetes
Main finding · Survival to dischargeResult — go to the resultAOR for survival to discharge 5.37 95% CI 2.13–13.53Authors' conclusion
In IHCA patients with T2DM, administration of metformin within 24 h before IHCA was independently associated with survival to discharge.
Study context
- Population
- Adult in-hospital cardiac arrest (IHCA) patients with type 2 DM (T2DM), April 2017 to March 2022
- Participants
- 377 patients
- Exposure
- Metformin vs no metformin within 24 h before IHCA
- Outcome
- Survival to discharge
Methodological detailsmultivariable logistic regression
- Multivariable logistic regression
Main finding
As reported in the abstract
AOR for survival to discharge
5.37
95% CI 2.13–13.53
P < 0.001
By group
Metformin vs No metformin
aOR for survival to discharge 5.37 (95% CI 2.13–13.53); P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Metformin | No metformin | aOR (95% CI) | P value | |
|---|---|---|---|---|---|
| Good neurologic outcome | 18.9% | 6.2% | 3.57 (1.14–11.17) | P = 0.029 | |
| 0.050.21520Adjusted odds ratio (log scale) |
- Good neurologic outcome: unadjusted P = 0.004
Survival to discharge by metformin dose
- Highest survival to discharge with 500-1000 mg/day metformin
- P < 0.001
Original publication
Association between metformin and survival outcomes in in-hospital cardiac arrest patients with diabetes. J Crit Care. Published 21 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →